HIGHLIGHTS
- who: Najat Bouchmaa et al. from the Molecular Immuno-Pharmacology, Sultan Moulay Slimane University, Beni-Mellal, Institute of Imaging, University of Messina, Messina, Italy have published the paper: In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer, in the Journal: PLOS ONE of July/26,/2022
- what: In this study the cytotoxic activity (MTT assay) of two natural steroidal compounds protodioscin and dioscin against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468) was assessed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.